Li H, Cho Y, Taylor H, et al. - Researchers sought to report on the most common treatment modalities for endometriosis in adolescent and young adult females with biopsy-proven endometriosis via performing a retrospective medical record review of 91 women aged 14-25 who underwent laparoscopy for pelvic pain with biopsy-proven endometriosis at a tertiary hospital system. The most common initial treatment comprised oral contraceptives (OCPs) (64%), followed by levonorgestrel IUD (LNG-IUD) (10%). More frequently, younger patients were provided progestin-only formulations, likely due to concern of impaired skeletal growth with estrogen-containing therapy. Wide variation in current treatments was observed; the treatments included OCPs, LNG-IUD, oral progestins, elagolix, and leuprolide. Combination of these agents in regimens was common. While receipt of elagolix or leuprolide was recorded in one third (33%) of patients at some point in the treatment course, their treatment discontinuation rate was high (50%) possibly because of side effects or insurance coverage. Findings from this pilot study may aid defining the spectrum of optimal therapeutic regimens for endometriosis in adolescent females.